A5038795718- Advanced Breast Cancer Therapies
- Immune responses and vaccinations
- Lung Cancer Treatments and Mutations
- Vaccine Coverage and Hesitancy
- Virology and Viral Diseases
- HER2/EGFR in Cancer Research
- Childhood Cancer Survivors' Quality of Life
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Clinical practice guidelines implementation
- PARP inhibition in cancer therapy
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Primary Care and Health Outcomes
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Medical Imaging and Pathology Studies
- Acute Myeloid Leukemia Research
- Colorectal Cancer Screening and Detection
- Bone health and treatments
- Healthcare cost, quality, practices
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Medical Imaging Techniques and Applications
Betsi Cadwaladr University Health Board
2018-2024
Pfizer (United Kingdom)
2024
Pfizer (United States)
2024
Swansea University
2024
Ysbyty Gwynedd Hospital NHS Trust
2016-2020
University Hospitals of Morecambe Bay NHS Foundation Trust
2019
Ipswich Hospital
2019
Blackpool Teaching Hospitals NHS Foundation Trust
2019
The Christie NHS Foundation Trust
2019
Calderdale and Huddersfield NHS Foundation Trust
2019
<b>Objective</b> To examine in a randomised trial whether 25% difference mortality exists between 4.5 months and 3 years of age for children given two standard doses Edmonston-Zagreb measles vaccines at 9 compared with those one dose vaccine (current policy). <b>Design</b> Randomised controlled trial. <b>Setting</b> The Bandim Health Project, Guinea-Bissau, which maintains health demographic surveillance system an urban area. <b>Participants</b> 6648 aged who had received three...
BackgroundAdjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant non-inferior the 12-month regarding disease-free survival.MethodsThis study an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in UK. randomly assigned cancer,...
Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms the serine/threonine kinase AKT. The FAKTION trial investigated whether addition capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advanced breast cancer.
Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported improve progression-free survival in women with aromatase inhibitor-resistant oestrogen receptor (ER)-positive, HER2-negative advanced breast cancer. The benefit appeared be independent of the phosphoinositide 3-kinase (PI3K)/AKT/phosphatase and tensin homologue (PTEN) pathway alteration status tumours, as ascertained using assays available at time. Here, we report updated overall results, a prespecified...
<b>Objective</b> To examine the protective efficacy of measles vaccination in infants a low income country before 9 months age. <b>Design</b> Randomised clinical trial. <b>Participants</b> 1333 aged 4.5 months: 441 treatment group and 892 control group. <b>Setting</b> Urban area Guinea-Bissau. <b>Intervention</b> Measles using standard titre Edmonston-Zagreb vaccine at <b>Main outcome measures</b> Vaccine against infection, admission to hospital for measles, mortality <b>Results</b> 28%...
1005 Background: The PI3K/AKT signalling pathway is frequently activated in patients (pts) with estrogen receptor (ER) positive breast cancer (ER+BC) and has been implicated endocrine therapy resistance. Capivasertib (AZD5363) a highly-selective, oral, small molecule AKT inhibitor. FAKTION trial investigated the addition of capivasertib to fulvestrant for postmenopausal women ER+ HER2 negative BC after relapse or disease progression on an aromatase inhibitor (AI). Methods: investigator-led,...
The World Health Organization recommends administration of measles vaccine (MV) at age 9 months in low-income countries. We tested the virus antibody response 4.5, 9, 18, and 24 for children randomly assigned to receive standard-titer Edmonston-Zagreb MV 4.5 months, or 18 age. At age, 75% had nonprotective levels. Following receipt 77% (316/408) protective levels age; after a second dose 97% (326/337) In addition, both was inversely correlated with level first MV, received provided...
BACKGROUND: Previous studies from Africa have suggested that there is little benefit to be gained early two-dose measles vaccination schedules. Two-dose schedules been associated with no improvement in coverage due immunization of the same individuals on both occasions, low return rate, high refusal vaccine efficacy, and fear blunting antibody response. Because poor results achieved previously schedules, we studied patterns participation, reasons for non-participation, relative efficacy a...
1005 Background: Previous results from the Phase 2 FAKTION trial (NCT01992952) showed progression free survival (PFS) in patients with aromatase inhibitor (AI) resistant ER+/HER2− advanced breast cancer was significantly longer fulvestrant plus capivasertib vs placebo. At time of analysis, PFS benefit associated not restricted to activating mutations PIK3CA (E542K, E545K, H1047R or H1047L) PTEN protein null. We report now mature overall (OS) data enhanced biomarker analysis. Methods: For...
Healthy lifestyle interventions have a positive impact on multiple disease trajectories, including cancer-related outcomes. Specifically, appropriate habitual physical activity, adequate sleep, and regular wholesome diet are of paramount importance for the wellness supportive care survivors cancer. Mobile health (mHealth) apps potential to support novel tailored interventions.
<title>Abstract</title> Objective: To develop a sustainable, scalable methodology for the design of outcome-based agreements (OBAs) that works on ground and dynamically overcomes historical challenges. Methods: Project IDEATE co-created solutions to known (and emergent) challenges via iterative workshops real-world data analysis refine hypothetical model an OBA in trusted research environment. A cross-disciplinary collaboration between NHS Wales, industry, academia was developed. Data were...
To develop a sustainable, scalable methodology for the design of outcome-based agreements (OBAs) that works on ground and dynamically overcomes historical challenges.
<h3>ABSTRACT</h3> Breast cancer diagnosed during pregnancy is a relatively uncommon event. This challenging situation presents clinicians with difficult decisions, often requiring multidisciplinary approach at time of heightened anxiety for the patient and their family. paper describes case young woman metastatic breast in early pregnancy, outlines how this complex clinical was managed.
<sec> <title>BACKGROUND</title> Healthy lifestyle interventions have a positive impact on multiple disease trajectories, including cancer-related outcomes. Specifically, appropriate habitual physical activity, adequate sleep, and regular wholesome diet are of paramount importance for the wellness supportive care survivors cancer. Mobile health (mHealth) apps potential to support novel tailored interventions. </sec> <title>OBJECTIVE</title> This observational pilot study aims assess...
Abstract This abstract was withdrawn by the authors. Citation Format: Howell SJ, Waters S, Twelves C, Joffe J, Moon Bale Venkitaraman R, Bezecny P, Casbard A, Wilhelm-Benartzi Carucci M, Butler Alchami F, Jones R. Withdrawn [abstract]. In: Proceedings of 2018 San Antonio Breast Cancer Symposium; Dec 4-8; Antonio, TX. Philadelphia (PA): AACR; Res 2019;79(4 Suppl):Abstract nr PD1-07.